Abstract
Introduction
The advent of immune checkpoint inhibitors in the treatment of certain types of cancers has revolutionized cancer therapy. In general, these novel agents are more tolerable and have better safety profiles than conventional chemotherapy agents. Although a low incidence of myocarditis was noted as a side effect of immune checkpoint inhibitors in clinical trials, it is being increasingly cited in the literature as their use also increases.
Methods
Using a combination of search terms in the PubMed/Medline database and manual searches on Google Scholar and the bibliographies of articles identified, we reviewed all cases reported in the English language citing myocarditis associated with either pembrolizumab, nivolumab, ipilimumab, or any combination of these agents.
Results
A total of 42 cases were included in the study. Mean age was 65.5 years; 64% were male, 36% were female. One or two doses preceded the onset of myocarditis in 33% and 29% of cases, respectively. Steroids were used as the first-line therapy in 90% of cases. Complete heart block occurred in 36% of cases. Fourteen (33%) deaths were reported, with 64% and 29% of deaths occurring after one or two doses, respectively.
Conclusion
Most cases and fatalities of myocarditis occurred shortly after initiation of immune checkpoint inhibitor therapy. Arrhythmias, particularly complete heart block, appear to be related to the occurrence of more severe and fatal cases. The use of serial electrocardiograms or biomarkers of myocardial injury may be crucial in detecting early stages of the disease process. Further research establishing more specific guidelines is necessary in dealing with this potentially fatal side effect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arangalage D, Delyon J, Lermuzeaux M, Ekpe K, Ederhy S, Pages C, Lebbe C (2017) Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 167:683–684. https://doi.org/10.7326/L17-0396
Baldetti L, Melillo F, Beneduce A, Camici PG (2018) Combined checkpoint inhibitor-associated myocarditis and pulmonary vasculitis mimicking acute pulmonary embolism. Eur Heart J Cardiovasc Imaging. https://doi.org/10.1093/ehjci/jey191
Behling J, Kaes J, Munzel T, Grabbe S, Loquai C (2017) New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res 27:155–158. https://doi.org/10.1097/cmr.0000000000000314
Berg DD, Vaduganathan M, Nohria A, Davids MS, Alyea EP, Torre M, Padera RF Jr (2017) Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. Eur J Heart Fail 19:682–685. https://doi.org/10.1002/ejhf.806
Blauwet LA, Cooper LT (2010) Myocarditis. Prog Cardiovasc Dis 52:274–288. https://doi.org/10.1016/j.pcad.2009.11.006
Bracamonte-Baran W, Cihakova D (2017) Cardiac autoimmunity: myocarditis. Adv Exp Med Biol 1003:187–221. https://doi.org/10.1007/978-3-319-57613-8_10
Brahmer JR, Lacchetti C, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 14:247–249. https://doi.org/10.1200/JOP.18.00005
Caforio AL et al (2007) A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 28:1326–1333. https://doi.org/10.1093/eurheartj/ehm076
Caforio ALP, Malipiero G, Marcolongo R, Iliceto S (2017) Myocarditis: a clinical overview. Curr Cardiol Rep 19:63. https://doi.org/10.1007/s11886-017-0870-x
Chen Q, Huang DS, Zhang LW, Li YQ, Wang HW, Liu HB (2018) Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol (Phila) 56:667–671. https://doi.org/10.1080/15563650.2017.1401079
Collin M (2016) Immune checkpoint inhibitors: a patent review (2010-2015). Expert Opin Ther Pat 26:555–564. https://doi.org/10.1080/13543776.2016.1176150
Cooper LT et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 50:1914–1931. https://doi.org/10.1016/j.jacc.2007.09.008
Copeland-Halperin R, Sahni GD (2018) Autoimmune Myocarditis With AV Block: Too Much of a Good Thing? JACC
Cristina AADLA, Escudier-Villa JM, Ortega Marcos J, Silva-Melchor L (2017) Progressive exertional dyspnea and fatigue in an oncology-patient. Austin J Clin Cardiolog 4(2):1058
Curtis JR et al (2007) Heart failure among younger rheumatoid arthritis and Crohn’s patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 46:1688–1693. https://doi.org/10.1093/rheumatology/kem212
Escudier M et al (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085–2087. https://doi.org/10.1161/CIRCULATIONAHA.117.030571
Farhad H et al (2016) Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging 9:15. https://doi.org/10.1161/circimaging.115.003584
Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, Hare JM (2000) Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 36:227–232
Frigeri M et al (2018) Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. Can J Cardiol 34:92 e91–92 e93. https://doi.org/10.1016/j.cjca.2017.09.025
Fukasawa Y et al (2017) Nivolumab-induced myocarditis concomitant with myasthenia gravis. Case Rep Oncol 10:809–812. https://doi.org/10.1159/000479958
Fung G, Luo H, Qiu Y, Yang D, McManus B (2016) Myocarditis. Circ Res 118:496–514. https://doi.org/10.1161/CIRCRESAHA.115.306573
Gallegos C, Rottmann D, Nguyen VQ, Baldassarre LA (2019) Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate. Eur Heart J Case Rep. https://doi.org/10.1093/ehjcr/yty149
Ganatra S, Neilan TG (2018) Immune checkpoint inhibitor-associated myocarditis. Oncologist 23:879–886. https://doi.org/10.1634/theoncologist.2018-0130
Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR (2015) Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 3:4. https://doi.org/10.1186/s40425-015-0048-2
Gibson R, Delaune J, Szady A, Markham M (2016) Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep. https://doi.org/10.1136/bcr-2016-216228
Guglin M, Nallamshetty L (2012) Myocarditis: diagnosis and treatment. Curr Treat Options Cardiovasc Med 14:637–651. https://doi.org/10.1007/s11936-012-0204-7
Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29–39. https://doi.org/10.1016/j.intimp.2018.06.001
Hauck AJ, Kearney DL, Edwards WD (1989) Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc 64:1235–1245
Heinzerling L et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50. https://doi.org/10.1186/s40425-016-0152-y
Imai R, Ono M, Nishimura N, Suzuki K, Komiyama N, Tamura T (2018) Fulminant myocarditis caused by an immune checkpoint inhibitor: a case report with pathological findings. J Thorac Oncol 15:15. https://doi.org/10.1016/j.jtho.2018.10.156
Inayat F, Masab M, Gupta S, Ullah W (2018) New drugs and new toxicities: pembrolizumab-induced myocarditis. BMJ Case Rep. https://doi.org/10.1136/bcr-2017-223252
Jain V, Mohebtash M, Rodrigo ME, Ruiz G, Atkins MB, Barac A (2018) Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. J Immunother 41:332–335. https://doi.org/10.1097/CJI.0000000000000239
Janardhanan R (2016) Myocarditis with very high troponins: risk stratification by cardiac magnetic resonance. J Thorac Dis 8:E1333–E1336. https://doi.org/10.21037/jtd.2016.10.60
Johnson DB et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755. https://doi.org/10.1056/NEJMoa1609214
Katsume Y, Isawa T, Toi Y, Fukuda R, Kondo Y, Sugawara S, Ootomo T (2018) Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern Med 57:3157–3162. https://doi.org/10.2169/internalmedicine.0255-17
Kindermann I et al (2012) Update on myocarditis. J Am Coll Cardiol 59:779–792. https://doi.org/10.1016/j.jacc.2011.09.074
Kobashigawa JA et al (2006) Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transpl 6:1377–1386. https://doi.org/10.1111/j.1600-6143.2006.01290.x
Kobashigawa J et al (2011) Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transpl 30:252–269. https://doi.org/10.1016/j.healun.2010.11.003
Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3:11. https://doi.org/10.1186/s40425-015-0057-1
Lauer B, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP (1997) Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 30:1354–1359
Lopez EM, Dunn S, Mazimba S (2018) Malignant arrhythmias in autoimmune myocarditis secondary to immune checkpoint blockade treatment. J Am College Cardiol 71:A2375. https://doi.org/10.1016/S0735-1097(18)32916-4
Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A (2007) CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res 101:248–257. https://doi.org/10.1161/circresaha.106.147124
Mahmood SS et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755–1764. https://doi.org/10.1016/j.jacc.2018.02.037
Mahrholdt H et al (2004) Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109:1250–1258. https://doi.org/10.1161/01.CIR.0000118493.13323.81
Martinez-Calle N et al (2018) Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica 103:318–321. https://doi.org/10.3324/haematol.2017.185777
Matson DR, Accola MA, Rehrauer WM, Corliss RF (2018) Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab. J Forensic Sci 63:954–957. https://doi.org/10.1111/1556-4029.13633
Mehta A, Gupta A, Hannallah F, Koshy T, Reimold S (2016) Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma. Melanoma Res 26:319–320. https://doi.org/10.1097/CMR.0000000000000251
Monge C et al (2018) Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. J Immunother Cancer 6:150. https://doi.org/10.1186/s40425-018-0473-0
Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933. https://doi.org/10.1016/S0140-6736(18)30533-6
Nasr F, El Rassy E, Maalouf G, Azar C, Haddad F, Helou J, Robert C (2018) Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. Eur J Cancer 91:171–173. https://doi.org/10.1016/j.ejca.2017.11.026
Nieminen MS, Heikkila J, Karjalainen J (1984) Echocardiography in acute infectious myocarditis: relation to clinical and electrocardiographic findings. Am J Cardiol 53:1331–1337
Norwood TG et al (2017) Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5:91. https://doi.org/10.1186/s40425-017-0296-4
Okazaki T et al (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9:1477–1483. https://doi.org/10.1038/nm955
Reuben A et al (2017) Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6:e1361097. https://doi.org/10.1080/2162402X.2017.1361097
Rodriguez ER, Skojec DV, Tan CD, Zachary AA, Kasper EK, Conte JV, Baldwin WM 3rd (2005) Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transpl 5:2778–2785. https://doi.org/10.1111/j.1600-6143.2005.01074.x
Rota E et al (2019) Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life-threatening continuum of neuromuscular and cardiac toxicity. eNeurological Sci 14:4–5. https://doi.org/10.1016/j.ensci.2018.11.023
Sakai T, Sasada S, Jyo C, Ishioka K, Takahashi S, Nakamura M (2017) Acute myocarditis and pericarditis after nivolumab treatment in patients with non-small cell lung cancer. Ann Oncol 28:mdx697.072–mdx697.072. https://doi.org/10.1093/annonc/mdx697.072
Samara Y, Yu CL, Dasanu CA (2018) Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma. J Oncol Pharm Pract 15:1078155218755868. https://doi.org/10.1177/1078155218755868
Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohe C (2016) Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer 99:117–119. https://doi.org/10.1016/j.lungcan.2016.06.025
Simsek M, Tekin SB, Bilici M (2019) Immunological agents used in cancer treatment. Eurasian J Med 51:90–94. https://doi.org/10.5152/eurasianjmed.2018.18194
Tadokoro T, Keshino E, Mohri M (2016) A case of acute myocarditis during treatment with anti-PD-1 antibody nivolumab in a melanoma patient. J Cardiac Fail 22:220. https://doi.org/10.1016/j.cardfail.2016.07.355
Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L (2018) Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy. J Immunother 41:35–38. https://doi.org/10.1097/CJI.0000000000000190
Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH (2012) PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188:4876–4884. https://doi.org/10.4049/jimmunol.1200389
Tay RY, Blackley E, McLean C, Moore M, Bergin P, Gill S, Haydon A (2017) Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer 117:921–924. https://doi.org/10.1038/bjc.2017.253
Thibault C, Vano Y, Soulat G, Mirabel M (2018) Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. Eur Heart J 39:3553. https://doi.org/10.1093/eurheartj/ehy485
Varricchi G et al (2017) Cardiotoxicity of immune checkpoint inhibitors ESMO Open 2:e000247. https://doi.org/10.1136/esmoopen-2017-000247
Weber JS (2012) Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ 15:174–177. https://doi.org/10.14694/edbook_am.2012.32.174
Yamaguchi S et al (2018) Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab. Can J Cardiol 34:812.e811–812.e813. https://doi.org/10.1016/j.cjca.2018.03.007
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Atallah-Yunes, S.A., Kadado, A.J., Kaufman, G.P. et al. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol 145, 1527–1557 (2019). https://doi.org/10.1007/s00432-019-02927-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-019-02927-x